MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - STERLING BIOTECH
SUN PHARMA vs STERLING BIOTECH - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
STERLING BIOTECH 
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Current Valuations
| SUN PHARMA | STERLING BIOTECH | SUN PHARMA/ STERLING BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 28.7 | -0.4 | - | View Chart |
| P/BV | x | 2.9 | 0.0 | 20,380.6% | View Chart |
| Dividend Yield | % | 0.6 | 0.0 | - |
Financials
 SUN PHARMA  STERLING BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-19 |
STERLING BIOTECH Dec-13 |
SUN PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 679 | 11 | 6,464.8% | |
| Low | Rs | 375 | 3 | 11,041.2% | |
| Sales per share (Unadj.) | Rs | 121.1 | 26.8 | 451.9% | |
| Earnings per share (Unadj.) | Rs | 13.4 | -15.0 | -89.4% | |
| Cash flow per share (Unadj.) | Rs | 20.7 | -5.5 | -378.6% | |
| Dividends per share (Unadj.) | Rs | 2.75 | 0 | - | |
| Dividend yield (eoy) | % | 0.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 172.6 | 54.9 | 314.5% | |
| Shares outstanding (eoy) | m | 2,399.26 | 267.87 | 895.7% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.4 | 0.3 | 1,678.2% | |
| Avg P/E ratio | x | 39.4 | -0.5 | -8,480.3% | |
| P/CF ratio (eoy) | x | 25.5 | -1.3 | -2,003.0% | |
| Price / Book Value ratio | x | 3.1 | 0.1 | 2,411.7% | |
| Dividend payout | % | 20.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,264,650 | 1,862 | 67,929.9% | |
| No. of employees | `000 | 17.5 | 1.4 | 1,292.5% | |
| Total wages/salary | Rs m | 59,671 | 547 | 10,912.7% | |
| Avg. sales/employee | Rs Th | 16,608.1 | 5,303.3 | 313.2% | |
| Avg. wages/employee | Rs Th | 3,409.6 | 403.8 | 844.3% | |
| Avg. net profit/employee | Rs Th | 1,833.8 | -2,959.0 | -62.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 290,659 | 7,181 | 4,047.8% | |
| Other income | Rs m | 10,255 | 43 | 24,072.5% | |
| Total revenues | Rs m | 300,914 | 7,223 | 4,165.9% | |
| Gross profit | Rs m | 63,076 | 947 | 6,661.3% | |
| Depreciation | Rs m | 17,533 | 2,543 | 689.4% | |
| Interest | Rs m | 5,553 | 4,377 | 126.9% | |
| Profit before tax | Rs m | 50,246 | -5,931 | -847.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -12,144 | 0 | - | |
| Tax | Rs m | 6,009 | -1,924 | -312.3% | |
| Profit after tax | Rs m | 32,093 | -4,007 | -801.0% | |
| Gross profit margin | % | 21.7 | 13.2 | 164.6% | |
| Effective tax rate | % | 12.0 | 32.4 | 36.9% | |
| Net profit margin | % | 11.0 | -55.8 | -19.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 310,692 | 14,335 | 2,167.4% | |
| Current liabilities | Rs m | 173,396 | 49,809 | 348.1% | |
| Net working cap to sales | % | 47.2 | -494.0 | -9.6% | |
| Current ratio | x | 1.8 | 0.3 | 622.6% | |
| Inventory Days | Days | 99 | 403 | 24.6% | |
| Debtors Days | Days | 112 | 171 | 65.4% | |
| Net fixed assets | Rs m | 232,477 | 55,432 | 419.4% | |
| Share capital | Rs m | 2,399 | 268 | 895.6% | |
| "Free" reserves | Rs m | 411,691 | 13,935 | 2,954.3% | |
| Net worth | Rs m | 414,091 | 14,701 | 2,816.7% | |
| Long term debt | Rs m | 15,226 | 9,478 | 160.6% | |
| Total assets | Rs m | 646,938 | 73,988 | 874.4% | |
| Interest coverage | x | 10.0 | -0.4 | -2,831.1% | |
| Debt to equity ratio | x | 0 | 0.6 | 5.7% | |
| Sales to assets ratio | x | 0.4 | 0.1 | 462.9% | |
| Return on assets | % | 5.8 | 0.5 | 1,161.7% | |
| Return on equity | % | 7.8 | -27.3 | -28.4% | |
| Return on capital | % | 10.2 | -6.4 | -158.2% | |
| Exports to sales | % | 0 | 25.9 | 0.0% | |
| Imports to sales | % | 0 | 0.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
| Imports (cif) | Rs m | NA | 12 | 0.0% | |
| Fx inflow | Rs m | 66,025 | 1,860 | 3,550.1% | |
| Fx outflow | Rs m | 38,610 | 25 | 155,123.3% | |
| Net fx | Rs m | 27,415 | 1,835 | 1,494.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 21,965 | 1,719 | 1,278.0% | |
| From Investments | Rs m | -6,813 | -3,148 | 216.4% | |
| From Financial Activity | Rs m | -27,305 | 1,426 | -1,914.8% | |
| Net Cashflow | Rs m | -8,442 | -3 | 248,279.4% | |
Share Holding
| Indian Promoters | % | 63.7 | 33.9 | 187.9% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.1 | 0.0 | - | |
| FIIs | % | 23.0 | 9.9 | 232.3% | |
| ADR/GDR | % | 0.0 | 16.9 | - | |
| Free float | % | 8.3 | 39.3 | 21.1% | |
| Shareholders | 133,026 | 21,482 | 619.2% | ||
| Pledged promoter(s) holding | % | 0.5 | 55.9 | 0.9% |
Compare SUN PHARMA With: STRIDES PHARMA SCIENCE AJANTA PHARMA UNICHEM LAB ALEMBIC PHARMA CADILA HEALTHCARE
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Marginally Higher; Energy and IT Stocks Witness Buying(Closing)
After opening the day on a strong note, Indian share markets erased most of the gains and turned highly volatile in the afternoon session.
Related Views on News
SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)
May 28, 2020 | Updated on May 28, 2020For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsMost Popular
How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)
Jul 2, 2020In the first of two videos, I'll show you how to identify the best stocks for intraday trading.
Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)
Jul 2, 2020Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...
A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)
Jun 30, 2020If you are a trader, you must watch out for this dangerous addiction.
Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)
Jul 3, 2020This is why I believe smallcaps are the place to be in the near future.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
SUN PHARMA SHARE PRICE
Jul 13, 2020 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 5-YR ANALYSIS
COMPARE SUN PHARMA WITH
FEATURED VIDEOS
![]( "What No One Told You About Finding the Best Penny Stocks")
What No One Told You About Finding the Best Penny Stocks![]( "Using Price Action to Identify Trading Opportunity in Defense Stocks")
Using Price Action to Identify Trading Opportunity in Defense Stocks![]( "Three Charts on One of the Quickest Bull Markets in History")
Three Charts on One of the Quickest Bull Markets in History![]( "This is Where You Will Find the Most Promising Bets for Post Covid Rebound")
This is Where You Will Find the Most Promising Bets for Post Covid Rebound![]( "Here")
Here's How You Can Make Big Money from Penny Stocks
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.